Blog

Eugene Shteyngarts of Floresta Retreats: Mindshifting Moments – Stream #1

Jun 14 • 1 min read

Psychedelic Invest has been broadening its content catalog of late, and we don’t plan to stop anytime soon. In fact, we plan to do more interviews, take on more topics, and continue to search for the answers that our audience continues to ask us about. A lot of people have been curious about what it’s…

Mindset Pharma Receives Notice of Allowance for Patent Application for Psilocin Derivatives

Jun 13 • 2 min read

Mindset Pharma Inc. (CSE: MSET | FSE: 9DF | OTCQB: MSSTF), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, announced that the United States Patent and Trademark Office (‘USPTO’) has issued a Notice of Allowance for Mindset’s patent application…

Nova Mentis and University of Central Florida to Develop Saliva Serotonin Assay

Jun 10 • 3 min read

Nova Mentis Life Science Corp. (CSE: NOVA | FSE: HN3Q | OTCQB: NMLSF), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is proud to announce that it has signed a research agreement with the University of Central Florida (UCF) Research Foundation to develop a saliva serotonin assay….

Dr. Chris Witowski, CEO of Psilera Bioscience, Sits in the Investor Hotseat: Stream #2

Jun 10 • 48 min read

Psychedelic Invest’s second Investor Hotseat live stream event aired live on Thursday, June 9th. Host, Dustin Robinson, of Iter Investments, was joined by Dr. Chris Witowski of Psilera Bioscience. Chris was asked a series of intense questions that kept his energy levels, and his sweat levels, high, This interview taught us a lot about all…

Tryp Therapeutics Announces Results of First Patient Dosed in Phase II Clinical Trial for Binge Eating Disorder

Jun 9 • 4 min read

Tryp Therapeutics, Inc. (CSE: TRYP | OTCQB: TRYPF), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today the initial data readout for the first patient dosed in its Phase II S.T.O.P. (Study of the Treatment of Overeating utilizing Psilocybin) trial. In collaboration with the University of Florida….

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448449450451452453454455456457458459460461462463464465466467468469470471472473474475476477478479480481482483484485486487488489490491492493494495496497498499500501502503504505506507508509510511512513514515516517518519520521522523524525526527528529530531532533534535536537538539540541542543544545546547548549550551552553554555556557558559560